Certara updates trial simulator software

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/BrianAJackson)
(Image: Getty/BrianAJackson)

Related tags: Certara, Adaptive designs, Clinical trial

Certara has launched version 2.3 of its Trial Simulator software, which allows users to model and simulate different clinical trial scenarios – and supports the implementation of adaptive design.

The Trial Simulator software supports a variety of trial designs, including parallel, n-by-n Latin square, and crossover designs with any number of treatment groups and periods, explained Certara​ Chief Commercial Officer Ellen Leinfuss.

“The study enrolls subjects from one or more study centers, each of which may draw subjects from a different subpopulation with different covariate distributions,”​ she told us.

“Subjects may be screened for trial inclusion based on covariate values and/or responses measured during an optional lead-in phase.

“Active phase treatments and observations may include any number of doses and measurements, scheduled at specific times or using a recurring cycle of times. Trial Simulator supports adaptive dosing schemes and covariate or response based dose adjustments,”​ Leinfuss said.

The US Food and Drug Administration (FDA) recently released draft guidance on the use of adaptive design in clinical trials​. The adaptive design draft guidance advises industry on the types of information FDA needs to evaluate the results from clinical trials with adaptive designs. This includes Bayesian adaptive designs and complex designs relying on computer simulations.

The European Medicines Agency (EMA) also recently updated​ its first-in-human (FIH) recommendations, which Certara’s quantitative systems pharmacology (QSP) approach builds on. The company earlier this year outlined​ the role of QSP in FIH clinical trial design in a “Letter to the Editor.” The EMA responded, welcoming the initiative shown and encouraging the use of mechanistic models. 

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars